U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C49H68N18O9S2.3C2H4O2
Molecular Weight 1297.465
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SETMELANOTIDE ACETATE

SMILES

CC(O)=O.CC(O)=O.CC(O)=O.C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O

InChI

InChIKey=PILXXDANZBQUJH-AKVBKPKISA-N
InChI=1S/C49H68N18O9S2.3C2H4O2/c1-26-41(70)63-37(20-30-22-55-25-59-30)46(75)64-35(18-28-10-4-3-5-11-28)44(73)62-34(15-9-17-57-49(53)54)43(72)65-36(19-29-21-58-32-13-7-6-12-31(29)32)45(74)66-38(40(50)69)23-77-78-24-39(47(76)60-26)67-42(71)33(61-27(2)68)14-8-16-56-48(51)52;3*1-2(3)4/h3-7,10-13,21-22,25-26,33-39,58H,8-9,14-20,23-24H2,1-2H3,(H2,50,69)(H,55,59)(H,60,76)(H,61,68)(H,62,73)(H,63,70)(H,64,75)(H,65,72)(H,66,74)(H,67,71)(H4,51,52,56)(H4,53,54,57);3*1H3,(H,3,4)/t26-,33+,34+,35-,36+,37+,38+,39+;;;/m1.../s1

HIDE SMILES / InChI

Molecular Formula C2H4O2
Molecular Weight 60.052
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C49H68N18O9S2
Molecular Weight 1117.309
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Setmelanotide (RM-493), is an investigational, first-in-class melanocortin-4 receptor (MC4R) agonist in development for the treatment of rare genetic disorders of obesity. Setmelanotide is thought to activate the MC4R, part of a key biological pathway in humans that regulates weight by increasing energy expenditure and reducing appetite. Variants in genes within the MC4 pathway are associated with unrelenting hunger, known as hyperphagia, and severe, early-onset obesity. Setmelanotide is a potential replacement therapy that may restore lost activity in the MC4 pathway, reestablishing weight and appetite control in patients with these rare genetic disorders.

Approval Year

PubMed

PubMed

TitleDatePubMed

Sample Use Guides

Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) patients with moderate to severe obesity: Subcutaneous injection, 3 mg, daily
Route of Administration: Other
Setmelanotide (RM-493) binds human MC4R with Ki value of 0.71 nM in radioligand binding assay and activated MC4R with EC50 value of 1.5 nM in intracellular cAMP production assay.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:05:16 UTC 2023
Edited
by admin
on Sat Dec 16 16:05:16 UTC 2023
Record UNII
224I1W20I7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SETMELANOTIDE ACETATE
USAN  
Common Name English
SETMELANOTIDE ACETATE [ORANGE BOOK]
Common Name English
Setmelanotide acetate [WHO-DD]
Common Name English
IMCIVREE
Brand Name English
RM-493 ACETATE
Code English
Code System Code Type Description
FDA UNII
224I1W20I7
Created by admin on Sat Dec 16 16:05:16 UTC 2023 , Edited by admin on Sat Dec 16 16:05:16 UTC 2023
PRIMARY
CAS
1504602-49-6
Created by admin on Sat Dec 16 16:05:16 UTC 2023 , Edited by admin on Sat Dec 16 16:05:16 UTC 2023
NON-SPECIFIC STOICHIOMETRY
RXCUI
2469248
Created by admin on Sat Dec 16 16:05:16 UTC 2023 , Edited by admin on Sat Dec 16 16:05:16 UTC 2023
PRIMARY
PUBCHEM
155491122
Created by admin on Sat Dec 16 16:05:16 UTC 2023 , Edited by admin on Sat Dec 16 16:05:16 UTC 2023
PRIMARY PUBCHEM
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY